Elisabetta Abruzzese

62PUBLICATIONS
185CO-AUTHORS
Molecular targetsMedical mycologyAtomic and molecular physicsImmunogenetics (incl. genetic immunology)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (62)

|May 27, 2026
Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

|May 13, 2026
The Path Forward in MF: Small Molecules in the Limelight.

|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

|Mar 26, 2026
Beyond ATP: asciminib and the allosteric path in CML.

Elisabetta Abruzzese

|Mar 25, 2026
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Paola Guglielmelli, Massimo Breccia, Francesco Mendicino

|Feb 21, 2026
Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Francesca Palandri, Venediktos Kapetanakis, Balázs Dobi

Pageof 11

Frequent Collaborators

27 joint publications

Massimo Breccia

27 joint publications

Mario Tiribelli

22 joint publications

Massimiliano Bonifacio

21 joint publications

Alessandra Iurlo